Outcome measures for artificial pancreas clinical trials: A consensus report

D.M. Maahs, B.A. Buckingham, J.R. Castle, A. Cinar, E.R. Damiano, E. Dassau, J. Hans De Vries, F.J. Doyle, S.C. Griffen, A. Haidar, L. Heinemann, R. Hovorka, Timothy W. Jones, C. Kollman, B. Kovatchev, B.L. Levy, R. Nimri, D.N. O'Neal, M. Philip, E. RenardS.J. Russell, S.A. Weinzimer, H. Zisser, J.W. Lum

Research output: Contribution to journalArticlepeer-review

180 Citations (Scopus)


© 2016 by the American Diabetes Association.Research on and commercial development of the artificial pancreas (AP) continue to progress rapidly, and the AP promises to become a part of clinical care. In this report, members of the JDRF Artificial Pancreas Project Consortium in collaboration with thewider AP community 1) advocate for the use of continuous glucose monitoring glucosemetrics as outcomemeasures in AP trials, in addition to HbA1c, and 2) identify a short set of basic, easily interpreted outcome measures to be reported in AP studies whenever feasible. Consensus on a broader range of measures remains challenging; therefore, reporting of additional metrics is encouraged as appropriate for individual AP studies or study groups. Greater consistency in reporting of basic outcome measures may facilitate the interpretation of study results by investigators, regulatory bodies, health care providers, payers, and patients themselves, thereby accelerating the widespread adoption of AP technology to improve the lives of people with type 1 diabetes.
Original languageEnglish
Pages (from-to)1175-1179
Number of pages5
JournalDiabetes Care
Issue number7
Publication statusPublished - 1 Jul 2016


Dive into the research topics of 'Outcome measures for artificial pancreas clinical trials: A consensus report'. Together they form a unique fingerprint.

Cite this